NewsVoir
Mumbai (Maharashtra), India — On May 22, as cancer remains an escalating public health issue, Metropolis Healthcare Limited, led by Ameera Shah and recognized as the country’s second-largest and most reputable diagnostics lab network, declared the introduction of
TruHealth Cancer Screen 360
–a thorough screening panel designed to transform
Preventive Oncology in India
.
For the first time in India’s diagnostic sector, the TruHealth Cancer Screen 360Male and Female Profiles have been meticulously developed to offer early detection insights. These profiles empower healthcare providers and patients alike with vital, practical data. The introduction of these tests underscores Metropolis’ dedication to improving accessibility to advanced screening options.
cancer diagnostics
while making them more budget-friendly and accessible.
As per GLOBOCAN 2022 data, cancer continues to be a significant worldwide public health issue. Within the South-East Asia region, India stands as the third highest country for new cancer cases and takes the second position for cancer-related deaths. Globally, it ranks at 121 regarding overall crude occurrence rates. Notably, less than 1 percent of Indian females undergo screenings for cervical, breast, and oral cancers—a figure drastically short of the WHO’s recommended threshold of 70%. This shortfall can largely be attributed to restricted medical accessibility, insufficient knowledge about preventive measures, and economic limitations which collectively impede broader participation in regular check-ups.
The TruHealth Cancer Screen 360 encompasses tumor markers, genetic predisposition testing for cancer risks, and specific screening components—like PSA tests for prostate cancer in males and at-home HPV sampling for cervical cancer in females. Tailored to tackle the increasing incidence of cancer and fill in critical diagnostic voids, this comprehensive test provides a layered, scientifically-backed method to identify early indications of prevalent cancers affecting both genders.
On the occasion of the launch, Mr. Surendran Chemmenkottil, CEO of Metropolis Healthcare Ltd., commented, “The unveiling of TruHealth Cancer Screen 360 Male and Female Profiles underscores our steadfast dedication to enhancing preventative care within India. Our objective is to provide people with prompt and accurate diagnostic resources so they can actively manage their well-being. Detecting cancer early plays a crucial role in lessening the impact of late-stage cases, boosting treatment success rates, and safeguarding lives. This move aligns perfectly with our strategy to broaden Metropolis’ presence in oncological diagnostics—a field growing ever more significant in medicine. We continue to prioritize delivering sophisticated testing options at an accessible cost for residents in both metropolitan and rural regions.”
A recent GLOBOCAN report has brought attention to a worrying pattern—the earlier development of cancer among urban residents. It shows an increase in cases like breast, cervical, and ovarian cancers among women, as well as lung and prostate cancers among men. Often these conditions aren’t identified until they have reached advanced stages, complicating treatments and leading to poorer prognoses.
Dr. Kirti Chadha, who serves as both the Senior Oncopathologist and Chief Scientific and Innovation Officer at Metropolis Healthcare Ltd., stated, “Given the increasing prevalence of gender-specific cancers like those affecting breasts, cervixes, and prostates, it’s crucial to incorporate specialized cancer screenings into regular health examinations. To address this necessity, we have introduced the TruHealth Cancer Screen 360—a thorough diagnostic solution grounded in scientific research. Unlike standard well-being tests, this advanced method assesses a wide range of biological markers along with genetic predispositions, enabling earlier detection of potential cancer threats even when no signs are present. Such proactive measures improve doctors’ ability to make informed decisions and equip patients with valuable information for prompt action, thus narrowing the gap from undetected illness stages to necessary treatments.”
Key aspects of TruHealth Cancer Screening 360 (For Male and Female Profiles)
* Gender-specific panels for breast, ovarian, cervical, liver, lung, prostate, colorectal, and thyroid cancers.
* A three-tier evaluation process integrating tumor indicators, genetic predisposition testing for over 25 different cancers, and targeted organ examinations.
* Cancer risk assessment via a Next Generation Sequencing panel that evaluates 317 genes, facilitating proactive steps for patients and their families.
* HPV Self-Sampling (Women’s Profile): Recommended by WHO, these self-testing devices serve as a primary method for cervical cancer screening—overcoming obstacles such as unease, scheduling issues, or limited facility availability.
* Access free genetic counseling sessions with accredited counselors designed to help individuals interpret their results and determine subsequent actions.
The TruHealth Cancer Screen 360 can be obtained at a special introductory rate, which is notably less than the total price of separate tests—thus making this sophisticated screening option more budget-friendly and widely available. Boasting a comprehensive lineup of more than 4,000 tests and panels, Metropolis remains at the forefront of diagnostic advancements. By launching this unified cancer screening program, the firm reinforces its commitment to promoting early detection, superior clinical outcomes, and preventative health measures for everyone.
Founded in 1981, Metropolis Healthcare Limited stands as India’s second largest diagnostics network under the guidance of pioneering head Ms. Ameera Shah. Over forty years, this enterprise has excelled at offering premier diagnostic solutions to clients ranging from individual patients to medical professionals and corporate entities throughout India and Africa. Its expansive presence covers 22 states, 3 union territories, and approximately 750 cities within India via an efficient infrastructure comprising over 210 labs, 4,500 collection centers, and upwards of 10,000 access points. Annually, Metropolis impacts countless lives through insightful health data aimed at enhancing therapeutic success rates. Their broad spectrum encompasses more than 4,000 test options covering sophisticated examinations such as those for oncology, neurology, infections, and hereditary conditions. Quality control remains paramount; they maintain a remarkable average CAP certification rating exceeding 98% during the last ten years, ranking them amongst global leaders in lab standards with only one percent outperforming their scores. At the core of Metropolis’ ethos lies dedication towards cutting-edge technology integration alongside fostering compassionate care delivery coupled with dependable testing documentation.
To learn more, please visit
www.metropolisindia.com
or click on
Twitter
,
Facebook
, or
LinkedIn
.
(ADVERTORIAL DISCLOSURE: The aforementioned press release has been supplied by
NewsVoir
ANI shall not bear any responsibility for the content thereof.
Provided by Syndigate Media Inc. (
Syndigate.info
).
Leave a Reply